Pioglitazone News and Research

RSS

Pioglitazone may help slow progression of artery wall thickening

A medication given to diabetics to improve their body's sensitivity to insulin also appears to slow the thickening of their artery walls, according to a study posted online by JAMA: The Journal of the American Medical Association.

13 Nov 2006

Thiazolidinediones may reduce cardiovascular risks

A drug commonly used to increase the body's sensitivity to insulin may slow the progression of cardiovascular disease in patients with type 2 diabetes, according to a study at the University of Illinois at Chicago College of Medicine.

13 Nov 2006

Alzheimer's disease linked to raised blood sugar levels

Researchers at an Alzheimer's Conference in Spain have come up with more information on the disease and just who amongst the population is most likely to get it.

17 Jul 2006

Pioglitazone shows promise in treating Alzheimer's

Treatment of high blood sugar may have a scientific connection to memory loss that could, one day, benefit millions of people with Alzheimer's Disease, which affects up to 4.5 million older Americans, bringing with it impaired thinking and memory.

17 Jul 2006

Impact of obesity on treatment of chronic hepatitis C

According to a new study, obese patients chronically infected with the hepatitis C virus (HCV) and treated with combination drug therapy may have better outcomes if the underlying abnormalities caused by excessive fat tissue are corrected.

6 Jun 2006

Latest diabetic medications more costly, but users have fewer hospital visits

Diabetics who were prescribed newer medications to control their illness were more likely to take these drugs as instructed than were other patients who were prescribed drugs that have been on the market for several decades.

22 Mar 2006

Study reveals mechanisms behind Thiazolidinediones used to treat type 2 diabetes

Thiazolidinediones (TZD's) are drugs commonly prescribed to patients with type 2 diabetes, the most common form of diabetes. Current U.S. Food and Drug Administration-approved agents are known as Actos (pioglitazone) and Avandia (rosiglitazone).

13 Mar 2006

Takeda wins patent infringement case

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc. have announced that Takeda's intellectual property rights have been successfully asserted against generic manufacturers seeking to challenge Takeda's patent rights to ACTOS (pioglitazone HCl).

24 Feb 2006

New device to detect early signs of heart conditions

A Yorkshire heart-monitor company is one of five technology businesses hoping to raise finance at the White Rose Bioscience Forum, Yorkshire’s flagship bioscience event - in York today (01 November 2005).

1 Nov 2005

Actos reduces the combined risk of non-fatal heart attacks, strokes in patients with type-2 diabetes

A study published in The Lancet shows that Takeda's Actos (pioglitazone HCl), an oral glucose lowering medication, significantly reduces the combined risk of non-fatal heart attacks, strokes and deaths by an additional 16% on top of standard medication

10 Oct 2005

Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in children

The Nonalcoholic Steatohepatitis (NASH) Clinical Research Network has launched its second clinical trial to study NASH, a liver disease that resembles alcoholic liver disease but occurs in patients who drink little or no alcohol. The first trial, launched in January of this year, focuses on adults, while the second trial studies the disease in children.

27 Sep 2005

Takeda Pharmaceuticals submits NDA for a new oral diabetes medication

Takeda Pharmaceuticals North America today announced that the company has submitted a New Drug Application (NDA) for a new oral medication that combines pioglitazone HCl and glimepiride, a sulfonylurea, to the United States Food and Drug Administration (FDA) for the treatment of type 2 diabetes.

30 Jun 2005

Insulin resistance drug with anti-inflammatory effects reduces risk factors

A drug, which reduces insulin resistance and also may have anti-inflammatory and other effects on blood vessels, lowered cardiovascular risk factors in patients with diabetes more than another diabetes medicine, even though both drugs improved blood sugar control equally, according to a new study (PDF) in the June 21, 2005, issue of the Journal of the American College of Cardiology.

21 Jun 2005

Muraglitazar lowers blood glucose and helps dyslipidemia seen in diabetes

A novel compound provides long-term lowering of blood glucose levels and improves plasma lipids (fats) that are often a problem in people with type 2 diabetes -- all in a once-daily pill, according to a report presented today at the American Diabetes Association's 65th Annual Scientific Sessions.

12 Jun 2005

Researchers describe emerging strategy for prevention, early treatment of Type 2 diabetes

Type 2 diabetes may be significantly delayed or prevented through medication that takes the load off of the body's delicate insulin-producing cells, according to a study released today by researchers at the Keck School of Medicine of the University of Southern California.

12 Jun 2005

New study suggests Pioglitazone HCl may significantly improve key predictors of cardiovascular risk

Study results published in the May 17th issue of Circulation, the journal of the American Heart Association, found that the diabetes medication pioglitazone HCl reduced carotid artery intima-media thickness (IMT). Patients taking pioglitazone also experienced significant reductions in insulin resistance, C-reactive protein (a marker for inflammation) and blood pressure, all of which contribute to the overall risk for cardiovascular disease.

9 May 2005

New trial for treatment of liver disease

The Nonalcoholic Steatohepatitis (NASH) Clinical Research Network is launching its first two clinical trials for the study of NASH, a liver disease that resembles alcoholic liver disease but occurs in patients who drink little or no alcohol.

3 Apr 2005

Rosiglitazone helps boost the effectiveness of a treatment for opening clogged arteries

Rosiglitazone, a drug taken to help improve blood sugar levels, also helps boost the effectiveness of a treatment for opening clogged arteries, according to a study in the November issue of Diabetes Care.

25 Oct 2004

Drug commonly used for diabetes might be effective in treating multiple sclerosis

Researchers at the University of Illinois at Chicago are launching a clinical trial to determine whether a drug commonly used for diabetes might be effective in treating multiple sclerosis, an autoimmune disease that affects 350,000 Americans.

10 Jun 2004

Addition of insulin sensitizer provides lipid benefits for patients with type 2 diabetes

Results of three studies show the oral anti-diabetic agent ACTOS (R) (pioglitazone HCl), in combination with a sulfonylurea, metformin or insulin, resulted in triglyceride decreases and high-density lipoprotein (HDL) cholesterol increases that demonstrated statistically significant improvements from baseline.

30 Apr 2004